Abstract
Purpose :
Multi-centre trials have demonstrated the efficacy of Aflibercept in the management of nAMD. There is no long term real life data available, on patient’s outcomes 3 years after the initiation of treatment. We carried out a retrospective study of visual and anatomical outcomes 3 years after initiating Aflibercept therapy.
Methods :
Retrospective analysis of 100 consecutive treatment naive eyes receiving intravitreal Aflibercept for the treatment of nAMD (April 2013-Nov 2016), at a single specialised ophthalmic centre in the north east of England, UK. In the first year, fixed dosing regimen was adhered to, with three monthly loading doses and a bimonthly regimen thereafter. Pro re nata (PRN) dosing regimen was followed after the first year. Visual acuity, OCT features, follow-up period and number of treatments received were noted.
Results :
One hundred eyes (96 patients) receiving Aflibercept treatment for nAMD were included. Mean age at presentation was 79.6 years with 60% diagnosed as Occult choroidal neo-vascular membrane. Mean follow up period was 142.9wks (48.4-174.4wks). Ten patients (10 eyes) had died at the time of this analysis. Seven eyes were switched to Ranibizumab. Stability of vision was achieved by 82% of patients with 12% of patients gaining >15letters. 79% of patients maintained the vision they attained at 12months. On average, patients received 11 injections. 66% of OCT’s were noted to be dry at last follow up.
Conclusions :
The real life outcomes confirm the long term effectiveness of Aflibercept in the treatment of nAMD after three years of treatment.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.